Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
Instituto Ramón Y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Cancer. 2023 Jun 15;129(12):1791-1794. doi: 10.1002/cncr.34752. Epub 2023 Apr 4.
Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple-negative breast cancer and the exciting results of antibody-drug conjugates. PLAIN LANGUAGE SUMMARY: The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer. Last year, the emergence of antibody-drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings.
虽然乳腺癌已经引领了精准医学的发展，但仍需要更多的研究来提高早期疾病患者的治疗效果，并在转移性疾病中延长生存时间，同时保持最佳的生活质量。去年，由于免疫疗法对三阴性乳腺癌患者生存的显著影响，以及抗体药物偶联物令人兴奋的结果，这些目标都取得了重大进展。
中文摘要：开发新的药物和生物标志物来选择那些将受益的患者对于提高乳腺癌患者的生存率至关重要。去年，抗体药物偶联物的出现以及免疫疗法在乳腺癌中的潜力再次得到肯定，是最重要的发现。
